Faeth Therapeutics, Inc. (FTH) · Oct 27, 2026 · Exec change

Faeth Therapeutics adds oncology R&D veteran to board

Oncology R&D director — Board expanded from six to seven; 25,000-share option granted

Faeth Therapeutics appoints oncology development veteran Adam Schayowitz as a director, strengthening oversight as PIKTOR moves toward major clinical milestones.

Faeth is a newly reshaped clinical-stage oncology company built around PIKTOR, an all-oral combination targeting the PI3K/AKT/mTOR pathway, with a Phase 2 endometrial-cancer study and a planned breast-cancer program as its next major proof points. This appointment adds development and commercialization depth, not a new clinical asset. Adam Schayowitz brings recent senior R&D leadership at Zymeworks and prior oncology development experience at Pfizer and Tesaro; the filing specifically cites his background in “oncology drug development, clinical and regulatory strategy and commercialization.” 〔0〕 The timing fits Faeth’s shift from rebuilding the corporate platform toward executing clinical milestones. The board now has seven directors, following another oncology-focused appointment in September, so the direction was becoming visible before this filing; the new information is the specific addition of a hands-on drug-development operator. The economic commitment is modest and standard. Schayowitz receives the normal director retainer plus an option for 25,000 shares, vesting monthly over three years and accelerating upon a change in control. Bottom line: This is a sensible governance upgrade ahead of PIKTOR’s clinical readouts, but it does not change the drug’s evidence, financing, or development timetable today. Its value is execution support rather than a new business catalyst by itself.

What to watch next

PIKTOR Phase 2 endometrial data, expected by year-end 2026

Original filing on SEC EDGAR

More Faeth Therapeutics, Inc. news

Faeth Therapeutics adds oncology R&D veteran to board | FTH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.